Login to Your Account

Third Rock founds kidney-focused Goldfinch with $55M series A

By Michael Fitzhugh
Staff Writer

Wednesday, December 14, 2016

Third Rock Ventures LLC has invested $55 million in a series A financing of Goldfinch Bio, a new Cambridge, Mass.-based company founded to discover and develop precision kidney disease therapies for conditions including focal segmental glomerulosclerosis and polycystic kidney disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription